At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed adenocarcinoma of the pancreas with advanced disease
- ✓Locally advanced disease must extend outside boundaries of standard radiation port
- ✓Not amenable to curative surgery or radiotherapy
- ✓Measurable disease: at least 1 unidimensional lesion ≥20 mm by conventional imaging or ≥10 mm by spiral CT
- ✕Prior bevacizumab or cetuximab
- ✕Prior vascular endothelial growth factor inhibitors
- ✕Prior gemcitabine
- ✕Prior erlotinib or other EGFR inhibitors
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Study of Bevacizumab (NSC# 704865) and Gemcitabine in Combination With Either Cetuximab (NSC# 714692) or OSI-774 (NSC# 718781) in Patients With Advanced Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating cetuximab, gemcitabine hydrochloride, and 2 other interventions for Adenocarcinoma of the Pancreas and 4 related conditions. Completed, enrolled 143 participants across 1 site.
Detailed Summary
This randomized phase II trial is studying bevacizumab, gemcitabine, and cetuximab to see how well they work compared to bevacizumab, gemcitabine, and erlotinib in treating patients with advanced pancreatic cancer. Monoclonal antibodies, such as cetuximab and bevacizumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining bevacizumab and gemcitabine with either cetuximab or erlotinib may kill more tumor cells.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Given orally